Allgemeine Informationen
  • Krankheitskategorie Infektionen und Parasitenbefall , Atemwegserkrankungen (nicht Krebs) (BASEC)
  • Rekrutierungsstatus Rekrutierung läuft (BASEC/ICTRP)
  • Studienstandort
    Aarau, Basel, Bellinzona, Bern, Chur, Freiburg, Genf, Lausanne, Luzern, St Gallen, Winterthur, Zürich
    (BASEC)
  • Studienverantwortliche PD Dr. Dr. med. Patrick M. Meyer Sauteur patrick.meyersauteur@kispi.uzh.ch (BASEC)
  • Datenquelle(n) BASEC: Import vom 24.03.2025 ICTRP: N/A
  • Letzte Aktualisierung 24.03.2025 15:10
HumRes65033 | SNCTP000005900 | BASEC2023-01295

A randomized controlled study on the use of antibiotics in children with pneumonia caused by mycoplasma

  • Krankheitskategorie Infektionen und Parasitenbefall , Atemwegserkrankungen (nicht Krebs) (BASEC)
  • Rekrutierungsstatus Rekrutierung läuft (BASEC/ICTRP)
  • Studienstandort
    Aarau, Basel, Bellinzona, Bern, Chur, Freiburg, Genf, Lausanne, Luzern, St Gallen, Winterthur, Zürich
    (BASEC)
  • Studienverantwortliche PD Dr. Dr. med. Patrick M. Meyer Sauteur patrick.meyersauteur@kispi.uzh.ch (BASEC)
  • Datenquelle(n) BASEC: Import vom 24.03.2025 ICTRP: N/A
  • Letzte Aktualisierung 24.03.2025 15:10

Zusammenfassung der Studie

In the MYTHIC Study, we want to find out whether the treatment of pneumonia caused by mycoplasma with antibiotics is really necessary. Pneumonia is caused by bacteria, viruses, or fungi. Antibiotic therapy is only effective against bacteria. Each antibiotic also works only against certain types of bacteria. Mycoplasmas (Mycoplasma pneumoniae) are one of the most common bacterial causes of pneumonia in children. The recommended antibiotics against mycoplasmas are macrolides, which are the second most commonly used antibiotics in children after penicillin antibiotics. However, the effectiveness of macrolides in children with mycoplasma pneumonia is unclear. The excessive use of macrolides has led to a global development of bacterial resistance to these antibiotics. Therefore, it is important to use antibiotics only when absolutely necessary. Based on clear evidence from previous studies, we assume that children receiving macrolides will take the same time to recover from mycoplasma infection as children receiving a placebo. The children will be closely monitored during the study, so participation in the study poses no risk to the children.

(BASEC)

Untersuchte Intervention

In this study, participants will be randomly assigned to two groups: Group 1 (experimental group) will receive a macrolide antibiotic and Group 2 (control group) will receive a placebo (medication without active ingredient). Neither the participants nor the investigators will know who has been assigned to which group. The idea is to minimize the influence on the results. Through these measures, we can objectively assess whether the placebo is not worse than the antibiotic. The study lasts 28 days and includes 2 additional examinations as well as 3 telephone check-ups.

(BASEC)

Untersuchte Krankheit(en)

A bacterial pneumonia is usually treated with antibiotics. Many antibiotics are no longer effective due to the development of bacterial resistance. In this study, we investigate whether the treatment of pneumonia caused by mycoplasmas with antibiotics is really necessary.

(BASEC)

Kriterien zur Teilnahme
- Children and adolescents aged 3-17 years presenting to the emergency department with pneumonia - Clinical diagnosis of pneumonia AND fever >38°C AND tachypnea (respiratory rate above age-specific reference values) - Positive screening test for mycoplasma infection - Written informed consent (BASEC)

Ausschlusskriterien
- Known intolerance to azithromycin - Underlying comorbidities: cystic fibrosis or other chronic lung diseases (excluding asthma), primary or secondary immunodeficiency, cardiovascular disease, or severe cerebral palsy or myasthenia gravis - History of recurrent pneumonia (two or more episodes) or severe pneumonia - Antibiotic treatment for mycoplasmas within the last 7 days - Transfer to intensive care directly from the emergency department - Inability to take oral medications - It is unlikely that parents will attend follow-up visits as part of the study and reliably complete questionnaires, e.g., due to language barriers or because they live far from the study site (BASEC)

Studienstandort

Aarau, Basel, Bellinzona, Bern, Chur, Freiburg, Genf, Lausanne, Luzern, St Gallen, Winterthur, Zürich

(BASEC)

nicht verfügbar

Sponsor

Christoph Berger - University Children's Hospital Zurich

(BASEC)

Kontakt für weitere Auskünfte zur Studie

Kontaktperson Schweiz

PD Dr. Dr. med. Patrick M. Meyer Sauteur

+41 44 266 78 96

patrick.meyersauteur@kispi.uzh.ch

University Children's Hospital Zurich

(BASEC)

Wissenschaftliche Auskünfte

nicht verfügbar

Name der bewilligenden Ethikkommission (bei multizentrischen Studien nur die Leitkommission)

Ethikkommission Zürich

(BASEC)

Datum der Bewilligung durch die Ethikkommission

14.05.2024

(BASEC)


ICTRP Studien-ID
nicht verfügbar

Offizieller Titel (Genehmigt von der Ethikkommission)
A randomized controlled non-inferiority trial of placebo versus macrolide antibiotics for Mycoplasma pneumoniae infection in children with community-acquired pneumonia - MYTHIC Study (BASEC)

Wissenschaftlicher Titel
nicht verfügbar

Öffentlicher Titel
nicht verfügbar

Untersuchte Krankheit(en)
nicht verfügbar

Untersuchte Intervention
nicht verfügbar

Studientyp
nicht verfügbar

Studiendesign
nicht verfügbar

Ein-/Ausschlusskriterien
nicht verfügbar

nicht verfügbar

Primäre und sekundäre Endpunkte
nicht verfügbar

nicht verfügbar

Registrierungsdatum
nicht verfügbar

Einschluss des ersten Teilnehmers
nicht verfügbar

Sekundäre Sponsoren
nicht verfügbar

Weitere Kontakte
nicht verfügbar

Sekundäre IDs
nicht verfügbar

Angaben zur Verfügbarkeit von individuellen Teilnehmerdaten
nicht verfügbar

Weitere Informationen zur Studie
nicht verfügbar

Ergebnisse der Studie

Zusammenfassung der Ergebnisse

nicht verfügbar

Link zu den Ergebnissen im Primärregister

nicht verfügbar